ES2012197A6 - Procedimiento para preparar derivados 17beta-oh-19-nor-esteroides sustituidos en 17alfa. - Google Patents

Procedimiento para preparar derivados 17beta-oh-19-nor-esteroides sustituidos en 17alfa.

Info

Publication number
ES2012197A6
ES2012197A6 ES8804011A ES8804011A ES2012197A6 ES 2012197 A6 ES2012197 A6 ES 2012197A6 ES 8804011 A ES8804011 A ES 8804011A ES 8804011 A ES8804011 A ES 8804011A ES 2012197 A6 ES2012197 A6 ES 2012197A6
Authority
ES
Spain
Prior art keywords
steroids
novel
beta
hydroxy
hal1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES8804011A
Other languages
English (en)
Inventor
Martine Moguilewsky
Lucien Nedelec
Francois Nique
Daniel Philibert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8718376A external-priority patent/FR2625505B2/fr
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Publication of ES2012197A6 publication Critical patent/ES2012197A6/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR DERIVADOS 17-BETA-OH-19-NOR-ESTEROIDES SUSTITUIDOS EN 17-ALFA DE FORMULA: EN LA QUE R'' REPRESENTA UN RADICAL PROPILO, PROPENILO, YODOETENILO, YODOETINILO O -C=C-CH2HAL1, DONDE HAL1 REPRESENTA UN ATOMO DE CLORO, FLUOR O BROMO, ASI COMOS SUS SALES, EN EL QUE SE HACE REACCIONAR UN REACTIVO DE BROMURACION O CLORURACION, TAL COMO TRIFENILFOSFINA CON TETRABROMURO O TETRACLORURO DE CARBONO, EN PRESENCIA DE UN DISOLVENTE TAL COMO TETRAHIDROFURANO O CLORURO DE METILENO, CON EL PRODUCTO DE FORMULA Y DESPUES SE CONTINUA LA REACCION CON UN REACTIVO DE CAMBIO DE HALOGENOS TAL COMO FLUORURO DE CESIO O POTASIO, EN PRESENCIA DE ETER CORONA-18-6 EN ACETONITRILO. SE DESCRIBEN OTRAS VIAS DE PREPARACION DE DICHOS COMPUESTOS, ASI COMO LA OBTENCION DE COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN. LOS COMPUESTOS (I) SON UTILES PARTICULARMENTE COMO ANTIGLUCOCORTICOIDES, ANDROGENOS, ANTI-ANDROGENOS Y ANTIPROGESTOMIMETICOS.
ES8804011A 1987-12-30 1988-12-29 Procedimiento para preparar derivados 17beta-oh-19-nor-esteroides sustituidos en 17alfa. Expired - Fee Related ES2012197A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8718376A FR2625505B2 (fr) 1981-01-09 1987-12-30 Nouveaux derives steroides substitues en 11beta leur procede de preparation et leur application comme medicaments et les compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
ES2012197A6 true ES2012197A6 (es) 1990-03-01

Family

ID=9358447

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8804011A Expired - Fee Related ES2012197A6 (es) 1987-12-30 1988-12-29 Procedimiento para preparar derivados 17beta-oh-19-nor-esteroides sustituidos en 17alfa.

Country Status (14)

Country Link
US (1) US5006518A (es)
JP (1) JP2785023B2 (es)
AT (1) AT396787B (es)
BE (1) BE1004905A4 (es)
CA (1) CA1303025C (es)
CH (1) CH676852A5 (es)
DE (1) DE3844408C2 (es)
ES (1) ES2012197A6 (es)
GB (1) GB2213484B (es)
GR (1) GR880100868A (es)
IT (1) IT1235358B (es)
LU (1) LU87417A1 (es)
NL (1) NL8803196A (es)
SE (1) SE503267C2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
DE4042004A1 (de) * 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
DE69500542T2 (de) * 1994-05-19 1998-01-02 Akzo Nobel Nv 11,21-Bisphenyl-19-nor-pregnan Derivate
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
JP2001301596A (ja) 2000-04-19 2001-10-31 Sumitomo Denko Brake Systems Kk 車両用液圧ブレーキシステムの制御方法
EP2253641A2 (en) * 2007-05-01 2010-11-24 Sicor, Inc. A process for preparing drospirenone and intermediate thereof
WO2011150209A1 (en) 2010-05-26 2011-12-01 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
CN107530435A (zh) 2015-03-02 2018-01-02 科赛普特治疗学股份有限公司 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
WO2016160969A1 (en) 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
US9829495B2 (en) 2015-08-13 2017-11-28 Corcept Therapeutics, Inc. Method for differentially diagnosing ACTH-dependent Cushing's syndrome
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11124537B2 (en) * 2015-12-23 2021-09-21 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
EP3394079A4 (en) 2015-12-23 2019-08-21 Oric Pharmaceuticals, Inc. INHIBITORS OF GLUCOCORTICOIDREZEPTORS
JP6765443B2 (ja) 2016-01-19 2020-10-07 コーセプト セラピューティクス， インコーポレイテッド 異所性クッシング症候群の鑑別診断
KR102237916B1 (ko) 2016-10-07 2021-04-09 오릭 파마슈티칼스, 인크. 글루코코르티코이드 수용체의 억제제
CA3065555A1 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
WO2022130015A2 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
ATE23167T1 (de) * 1981-01-09 1986-11-15 Roussel Uclaf In stellung 11 substituierte steroidzwischenprodukte und verfahren zu ihrer herstellung.
FR2528434B1 (fr) * 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
EP0116974B1 (de) * 1983-02-18 1986-10-29 Schering Aktiengesellschaft 11-Beta-Aryl-Estradiene, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
FR2549067B1 (fr) * 1983-06-14 1985-12-27 Roussel Uclaf Derives estradieniques radioactifs marques au tritium, leur procede de preparation et leur application pour l'etude et le dosage radio-immunologique de steroides dans les fluides biologiques
US4780461A (en) * 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
ES8502612A1 (es) * 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2566779B2 (fr) * 1984-06-29 1987-03-06 Roussel Uclaf Nouveaux derives steroides substitues en 11b, leur procede de preparation et leur application comme medicaments
DE3506785A1 (de) * 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3619413C2 (de) * 1986-06-10 2000-04-06 Schering Ag 9alpha, 10alpha-Methylen-Estrene, deren Herstellung und diese enthaltende pharmazeutische Präparate
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives

Also Published As

Publication number Publication date
AT396787B (de) 1993-11-25
JP2785023B2 (ja) 1998-08-13
DE3844408A1 (de) 1989-07-13
GB2213484B (en) 1991-10-09
CA1303025C (fr) 1992-06-09
LU87417A1 (fr) 1989-06-14
CH676852A5 (es) 1991-03-15
GR880100868A (el) 1994-03-31
US5006518A (en) 1991-04-09
NL8803196A (nl) 1989-07-17
SE503267C2 (sv) 1996-04-29
GB2213484A (en) 1989-08-16
JPH01213296A (ja) 1989-08-28
SE8804692D0 (sv) 1988-12-29
SE8804692L (sv) 1989-07-01
BE1004905A4 (fr) 1993-02-23
IT1235358B (it) 1992-06-30
DE3844408C2 (de) 2001-07-26
IT8848730A0 (it) 1988-12-29
GB8830380D0 (en) 1989-03-01
ATA318788A (de) 1993-04-15

Similar Documents

Publication Publication Date Title
ES2012197A6 (es) Procedimiento para preparar derivados 17beta-oh-19-nor-esteroides sustituidos en 17alfa.
ES8605821A1 (es) Un procedimiento para la preparacion de aciltripeptidos in- munoestimulantes
ES8704485A1 (es) Un procedimiento para la preparacion de derivados de piperazina 1,4-disustituidos.
YU48926B (sh) Postupak dobijanja sulfatne soli (2:1)3-
ES8700851A1 (es) Procedimiento para la obtencion de acido alquil-1- ciclopropil-1, 4-dihidro-4-oxo-3-quinolincarboxilico.
ES8802387A1 (es) Procedimiento para preparar (1,2,4)-triazolo (1,5-c) quinazolinas
ES8801230A1 (es) Un procedimiento para preparar un derivado de 1,5-benzotiazepina
ES8404356A1 (es) Procedimiento de preparacion de nuevas pirimido-quinoxalinas.
ES8607218A1 (es) Un procedimiento para preparar compuestos de amidina
EP0154508A3 (en) Thiophenylureas, their production and use
ES477785A1 (es) Procedimiento para la preparacion de nuevas 2-fenilimino- imidazolidinas sustituidas.
ES8800920A1 (es) Un procedimiento para preparar un derivado de 1,5-benzotiazepina
ES8802301A1 (es) Procedimiento para la obtencion de acidos 4-quinolon-3-carboxilicos 1,8- puenteados.
ES8205770A1 (es) Procedimiento para la preparacion de derivados de 2,3-indo- lediona
ES8502978A1 (es) Un procedimiento para preparar derivados de 5-halovinil-2'-desoxiuridina
ES8607224A1 (es) Un procedimiento para preparar esteres de acidos (alquilsulfonil)-metanosulfonicos
ES8505678A1 (es) Procedimiento para preparar pirido (1,2-c) imidazo-(1,2-a)bencimidazoles sustituidos
EP0216323A3 (en) Quinolonecarboxylic acid derivatives and their preparation
EP0221541A3 (en) Quinolonecarboxylic acid derivatives and their preparation
ES483269A1 (es) Un metodo de preparar sales de adicion de acido de esteres 2-aminoalcohilicos de acido benceno- y tiofeno-carbotioico
ES8705454A1 (es) Procedimiento para la obtencion de derivados del acido imidazoalquenoico
PT83307A (en) Spirobenzofuran-2 (3h),1'-cycloheptanes a process and interme diates for their preparation and their use as medicaments
ES8401488A1 (es) Procedimiento de preparacion de derivados de diaza-3,7a-cicloherta-(j,k)-fluorenos.
MY102089A (en) Antibacterial compounds.
JPS5430165A (en) 2-allylamino-5-phenyloxazoles and their pharmaceutically acceptable aicd salts

Legal Events

Date Code Title Description
SA6 Expiration date (snapshot 920101)

Free format text: 2008-12-29

FD1A Patent lapsed

Effective date: 20041230